Denali Therapeutics (DNLI) Shares Outstanding (Weighted Average) (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Shares Outstanding (Weighted Average) data on file, last reported at $186.6 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 9.0% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.6 million (up 9.0% YoY) and the FY2025 annual result came in at $172.6 million, up 21.05% from the prior year.
• Shares Outstanding (Weighted Average) improved to $186.6 million in Q1 2026 per DNLI's latest filing, from $172.6 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $186.6 million in Q1 2026 and bottomed at $122.7 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $142.6 million (2024), against an average of $149.4 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) rose 1.42%; it then advanced 23.43% in 2024.
• Tracing DNLI's Shares Outstanding (Weighted Average) over 5 years: stood at $125.5 million in 2022, then grew by 9.43% to $137.4 million in 2023, then grew by 3.83% to $142.6 million in 2024, then increased by 21.05% to $172.6 million in 2025, then gained by 8.1% to $186.6 million in 2026.
• Per Business Quant, the three latest DNLI Shares Outstanding (Weighted Average) figures stand at $186.6 million (Q1 2026), $172.6 million (Q4 2025), and $172.4 million (Q3 2025).

Peer Comparison